Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
European Journal of Cancer2017Vol. 86, pp. 82–90
Citations Over TimeTop 10% of 2017 papers
Xavier Pivot, Sunil Verma, Lesley Fallowfield, Volkmar Müller, Mikhail Lichinitser, Valerie Jenkins, Alfonso Sánchez Muñoz, Z. Machackova, Stuart Osborne, Joseph Gligorov
Related Papers
- → <p>Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis</p>(2019)12 cited
- → Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients(2020)5 cited
- → A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK(2001)3 cited
- → Advanced research on neoadjuvant therapy with trastuzumab in HER2-positive breast cancer(2014)